Last updated on April 2019

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy


Brief description of study

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

Clinical Study Identifier: NCT02864251

Find a site near you

Start Over

Local Institution

Kishiwada shi, Japan
3.43miles
  Connect »

Local Institution

Sakai-shi, Japan
9.29miles
  Connect »

Local Institution

Hirakata-shi, Japan
9.92miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.